利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.158 seconds)

    COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS 审中-公开
    用于治疗，预防和诊断癌症和其他增殖性疾病的组合物和方法

    公开(公告)号：WO2015089495A2

    公开(公告)日：2015-06-18

    申请号：PCT/US2014/070221

    申请日：2014-12-14

    Applicant: ANGIOGENEX, INC. ,  GARLAND, William, A. ,  CHAUDHARY, Jaideep ,  STOLLER, Glen

    Inventor： GARLAND, William, A. ,  CHAUDHARY, Jaideep ,  STOLLER, Glen

    IPC: A61K31/36

    CPC classification number: A61K31/36 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention provides methods for impairing function or reducing or ablating levels of Id (inhibitors of differentiation) proteins to suppress metastasis of cancer cells in mammalian subjects presenting with cancer or elevated risk of metastatic disease. Exemplary anti-Id compounds include N-(3-(benzo[d] [1,3]dioxol-5-yl)-3-(2-methoxyphenyl)propyl)-N- benzylpropionamide and isolated enantiomers of N-(3-(benzo[d] [ 1,3]dioxol-5-yl)-3-(2- methoxyphenyl)propyl)-N-benzylpropionamide. Anti-Id compositions and methods of the invention can be combined with standard anticancer treatment modalities, such as surgery, radiation and chemotherapy. Also provided are compositions and methods to treat other hyperproliferative disorders, including pathogenic angiogenic conditions, including tumor-associated neoangiogenesis and ocular vascular pathologies including age-related macular degeneration.

    Abstract translation: 本发明提供了降低或消除Id（分化抑制剂）蛋白质的功能或减少或消除水平的方法，以抑制具有癌症或升高的转移性疾病风险的哺乳动物受试者中癌细胞的转移。 示例性的抗Id化合物包括N-（3-（苯并[d] [1,3]二氧杂环戊烯-5-基）-3-（2-甲氧基苯基）丙基）-N-苄基丙酰胺和N-（3- （苯并[d] [1,3]二氧杂环戊烯-5-基）-3-（2-甲氧基苯基）丙基）-N-苄基丙酰胺。 本发明的抗Id组合物和方法可以与标准的抗癌治疗方式如手术，放射和化学疗法组合。 还提供了治疗其它过度增殖性疾病的组合物和方法，包括病原性血管生成病症，包括肿瘤相关的新血管生成和眼血管病变，包括年龄相关性黄斑变性。

    DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME
    2.
    发明申请
    DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME 审中-公开
    DOXORUBICIN ADJUVANTS降低毒性及使用方法

    公开(公告)号：WO2009102808A3

    公开(公告)日：2009-12-30

    申请号：PCT/US2009033825

    申请日：2009-02-11

    Applicant: TOSK INC ,  GARLAND WILLIAM A ,  FRENZEL BRIAN D

    Inventor： GARLAND WILLIAM A ,  FRENZEL BRIAN D

    IPC: A01N37/00

    CPC classification number: A61K31/15 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  C07C251/30 ,  C07C321/22 ,  C07C321/24 ,  C07C321/26 ,  C07C323/47 ,  A61K2300/00

    Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.

    Abstract translation: 提供了使用多柔比星活性剂的方法，其中观察到宿主毒性降低。 方法的一些方面包括向受试者施用有效量的多柔比星活性剂与多柔比星毒性降低佐剂（例如硝酮化合物）或硝酮化合物与双二氧代哌嗪化合物组合。 还提供了用于实践主题方法的组合物。 该方法和组合物可用于各种不同的应用，包括治疗各种不同的疾病状况。

    RABBIT MONOCLONAL ANTIBODY AGAINST ID1 PROTEIN
    4.
    发明申请
    RABBIT MONOCLONAL ANTIBODY AGAINST ID1 PROTEIN 审中-公开
    RABBIT单克隆抗体ID1蛋白

    公开(公告)号：WO2006138694A3

    公开(公告)日：2009-04-16

    申请号：PCT/US2006023715

    申请日：2006-06-15

    Applicant: BIOCHECK INC ,  CHEN JUNG-SHOU ,  GARLAND WILLIAM A

    Inventor： CHEN JUNG-SHOU ,  GARLAND WILLIAM A

    IPC: G01N33/53 ,  C07K16/18 ,  C07K16/30 ,  C12N5/12 ,  C12N15/13 ,  C12P21/08 ,  G01N33/543 ,  G01N33/574 ,  G01N33/577

    CPC classification number: C07K16/18 ,  C07K16/32 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/6872

    Abstract: The present invention relates to a rabbit monoclonal antibody that binds to human Id1 protein and/or mouse Id1 protein with high specificity and high affinity. The antibody has a binding constant, measured with respect to human Id1 protein and/or mouse Id1 protein, equal to or greater than 1x 108/molar. The antibody has no substantial cross-reactivity with other family Id proteins such as Id2, Id3, or Id4, or other endogenous proteins present in the cells that express Id1 protein. The high specificity and high affinity of the rabbit monoclonal antibodies of the present invention allows sensitive and specific detection and/or quantitation of Id1 protein in biological samples. The antibodies are useful in immunochemical-based assays such as ELISA, western blot, and immunohistochemical staining.

    Abstract translation: 本发明涉及以高特异性和高亲和力结合人Id1蛋白和/或小鼠Id1蛋白的兔单克隆抗体。 抗体具有相对于人Id1蛋白和/或小鼠Id1蛋白测量的结合常数，等于或大于1×108 /摩尔。 该抗体与其它家族Id蛋白如Id2，Id3或Id4或存在于表达Id1蛋白的细胞中存在的其它内源蛋白没有实质的交叉反应性。 本发明的兔单克隆抗体的高度特异性和高亲和力使生物样品中Id1蛋白的敏感和特异性检测和/或定量。 该抗体可用于基于免疫化学的测定，如ELISA，免疫印迹和免疫组织化学染色。

    RABBIT MONOCLONAL ANTIBODIES AGAINST MOUSE/HUMAN ID3 PROTEINS
    7.
    发明申请
    RABBIT MONOCLONAL ANTIBODIES AGAINST MOUSE/HUMAN ID3 PROTEINS 审中-公开
    RABBIT单克隆抗体针对小鼠/人类ID3蛋白

    公开(公告)号：WO2007089563A3

    公开(公告)日：2008-02-21

    申请号：PCT/US2007002137

    申请日：2007-01-26

    Applicant: BIOCHECK INC ,  ANGIOGENEX INC ,  CHEN JUNG-SHOU ,  GARLAND WILLIAM A

    Inventor： CHEN JUNG-SHOU ,  GARLAND WILLIAM A

    IPC: G01N33/53 ,  C07K16/18

    CPC classification number: C07K16/18 ,  G01N2333/4704

    Abstract: The present invention relates to a rabbit monoclonal antibody that binds to human Id3 protein and/or mouse Id3 protein with high specificity and high affinity. The antibody has a binding constant, measured with respect to human Id3 protein or mouse Id3, of greater than 1x 10 8 /molar. The antibody has no substantial cross-reactivity to other family Id proteins such as Id1, Id2, or Id4, or other endogenous proteins present in the cells that express Id3 protein. The specificity and high affinity of the rabbit monoclonal antibodies of the present invention allows sensitive and specific detection and/or quantitation of human or mouse Id3 protein in biological samples. The antibodies are useful in immunochemical-based assays such as ELISA, western blot, and immunohistochemical staining.

    Abstract translation: 本发明涉及以高特异性和高亲和力结合人Id3蛋白和/或小鼠Id3蛋白的兔单克隆抗体。 抗体相对于人Id3蛋白或小鼠Id3测量的结合常数大于1×10 8 /摩尔。 该抗体与其它家族Id蛋白如Id1，Id2或Id4或存在于表达Id3蛋白的细胞中存在的其它内源蛋白没有实质的交叉反应性。 本发明的兔单克隆抗体的特异性和高亲和性允许生物样品中人或小鼠Id3蛋白的敏感和特异性检测和/或定量。 该抗体可用于基于免疫化学的测定，如ELISA，免疫印迹和免疫组织化学染色。

    BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT
    8.
    发明申请
    BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT 审中-公开
    苯并噻嗪类治疗神经损伤性疾病治疗

    公开(公告)号：WO1996031462A1

    公开(公告)日：1996-10-10

    申请号：PCT/US1996004538

    申请日：1996-04-03

    Applicant: CENTAUR PHARMACEUTICALS, INC. ,  FLITTER, William, David ,  GARLAND, William, A. ,  WILCOX, Allan, L. ,  PAYLOR, Richard, E.

    Inventor： CENTAUR PHARMACEUTICALS, INC.

    IPC: C07C237/30

    CPC classification number: C07C237/38 ,  A61K31/166 ,  A61K31/167 ,  C07C233/65 ,  C07C237/30 ,  C07C237/42 ,  C07C2601/02

    Abstract: Disclosed are pharmaceutical compositions containing as active ingredient a compound of formula (I) wherein R' is a saturated alkyl of 3 to 5 carbon atoms, each R is independently -NO2 or -NH2 or -NHCOCH3, and n is 1 or 2. Some of these compounds are new. A process for their preparation is also disclosed, as well as their use in the manufacture of medicaments for treating conditions characterised by progressive loss of central nervous system such as Parkinson's disease or Alzheimer's.

    Abstract translation: 公开了含有作为活性成分的式（I）化合物的药物组合物，其中R'是3至5个碳原子的饱和烷基，每个R独立地是-NO 2或-NH 2或-NHCOCH 3，n是1或2.一些 的这些化合物是新的。 还公开了其制备方法，以及它们在制备用于治疗特征为中枢神经系统如帕金森病或阿尔茨海默病进行性丧失的病症的药物中的用途。

    CHEMICAL INHIBITORS OF INHIBITORS OF DIFFERENTIATION
    9.
    发明申请
    CHEMICAL INHIBITORS OF INHIBITORS OF DIFFERENTIATION 审中-公开
    抑制剂的化学抑制剂

    公开(公告)号：WO2009051801A2

    公开(公告)日：2009-04-23

    申请号：PCT/US2008/011881

    申请日：2008-10-17

    Applicant: ANGIOGENEX ,  CHAUDHARY, Jaideep ,  GARLAND, William, A.

    Inventor： CHAUDHARY, Jaideep ,  GARLAND, William, A.

    IPC: A61K48/00 ,  C12N15/12

    CPC classification number: A01K67/0271 ,  A01K2207/20 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/165 ,  A61K31/38 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention provides identification of inhibitors of inhibitors of differentiation (Id) for use in the treatment and prevention of diseases in mammals. The inhibitors of Id are effective alone in the treatment of a variety of cellular proliferative disorders including, but not limited to, diseases such as cancer, arthritis, age-related macular degeneration, psoriasis, neoplasms, angiomas, endometriosis, obesity, age-related macular degeneration, retinopathies, restenosis, scaring, fibrogenesis, fibrosis, cardiac remodeling, pulmonary fibrosis, scleroderma, failure associated with myocardial infarction, keloids, fibroid tumors and stenting. Additionally, these compounds are effective in blocking angiogenesis in tumor development, inducing apoptosis in malignant cells, inhibiting proliferation of cancer cells, increasing the effectiveness of chemotherapeutic agents, regulating transcriptional activity, reducing inflammation, increasing cellular differentiation, modulating ETS domain transcription factors, modulating PAX transcription factors, modulating TCF-ETS domain transcription factors, down regulating RAF-I /MAPK, upregulating JNK signaling pathways, and modulating cellular transformation.

    Abstract translation: 本发明提供用于治疗和预防哺乳动物疾病的分化抑制剂抑制剂（Id）的鉴定。 Id的抑制剂单独用于治疗各种细胞增殖性疾病，包括但不限于疾病如癌症，关节炎，年龄相关性黄斑变性，牛皮癣，肿瘤，血管瘤，子宫内膜异位症，肥胖症，年龄相关 黄斑变性，视网膜病变，再狭窄，惊厥，纤维发生，纤维化，心脏重塑，肺纤维化，硬皮病，与心肌梗塞相关的衰竭，瘢痕疙瘩，纤维瘤和支架置入术。 此外，这些化合物有效阻断肿瘤发展中的血管生成，诱导恶性细胞凋亡，抑制癌细胞增殖，增加化疗药物的有效性，调节转录活性，减少炎症，增加细胞分化，调节ETS结构域转录因子，调节 PAX转录因子，调节TCF-ETS结构域转录因子，调控RAF-I / MAPK，上调JNK信号通路，调节细胞转化。

Patent Agency Ranking